Hematologic Malignancies Detection - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510248160

Publication Date:

October 22, 2024

Pages:

115

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Hematological malignancy is a major disease that seriously endangers human health. With the invention and application of polymerase chain reaction, immunohistochemistry, next-generation sequencing and fluorescence in situ hybridization, its overall diagnostic level has been significantly improved.
The global market for Hematologic Malignancies Detection was estimated to be worth US$ 2234.7 million in 2023 and is forecast to a readjusted size of US$ 5801.1 million by 2030 with a CAGR of 14.6% during the forecast period 2024-2030
Increasing prevalence of hematological malignancies, emerging new technologies and methods for testing, patient preference for testing treatments, and increasing regulation across the healthcare industry are the key factors driving the growth of hematological malignancies testing market revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hematologic Malignancies Detection, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Hematologic Malignancies Detection by region & country, by Type, and by Application.
The Hematologic Malignancies Detection market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hematologic Malignancies Detection.
Market Segmentation
By Company
ArcherDx
Bio-Rad Laboratories
sysmex
Invitae
NeoGenomics Laboratories
Abbott Laboratories
Cancer Genetics
Adaptive Biotechnologies Corporation
Asuragen
Invivoscribe
Nanjing Shihejiyin Technology
Annaroad Gene Technology
BGI Genomics
Segment by Type:
Polymerase Chain Reaction
Immunochemistry
Next Generation Sequencing
Fluorescence in Situ Hybridization
Others
Segment by Application
Multiple Myeloma
Myelodysplastic Syndrome
Leukemia
Myeloproliferative Neoplasms
Lymphoma
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Hematologic Malignancies Detection manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Hematologic Malignancies Detection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Hematologic Malignancies Detection in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Hematologic Malignancies Detection Product Introduction
1.2 Global Hematologic Malignancies Detection Market Size Forecast
1.3 Hematologic Malignancies Detection Market Trends & Drivers
1.3.1 Hematologic Malignancies Detection Industry Trends
1.3.2 Hematologic Malignancies Detection Market Drivers & Opportunity
1.3.3 Hematologic Malignancies Detection Market Challenges
1.3.4 Hematologic Malignancies Detection Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Hematologic Malignancies Detection Players Revenue Ranking (2023)
2.2 Global Hematologic Malignancies Detection Revenue by Company (2019-2024)
2.3 Key Companies Hematologic Malignancies Detection Manufacturing Base Distribution and Headquarters
2.4 Key Companies Hematologic Malignancies Detection Product Offered
2.5 Key Companies Time to Begin Mass Production of Hematologic Malignancies Detection
2.6 Hematologic Malignancies Detection Market Competitive Analysis
2.6.1 Hematologic Malignancies Detection Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Hematologic Malignancies Detection Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematologic Malignancies Detection as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Polymerase Chain Reaction
3.1.2 Immunochemistry
3.1.3 Next Generation Sequencing
3.1.4 Fluorescence in Situ Hybridization
3.1.5 Others
3.2 Global Hematologic Malignancies Detection Sales Value by Type
3.2.1 Global Hematologic Malignancies Detection Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Hematologic Malignancies Detection Sales Value, by Type (2019-2030)
3.2.3 Global Hematologic Malignancies Detection Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Multiple Myeloma
4.1.2 Myelodysplastic Syndrome
4.1.3 Leukemia
4.1.4 Myeloproliferative Neoplasms
4.1.5 Lymphoma
4.1.6 Others
4.2 Global Hematologic Malignancies Detection Sales Value by Application
4.2.1 Global Hematologic Malignancies Detection Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Hematologic Malignancies Detection Sales Value, by Application (2019-2030)
4.2.3 Global Hematologic Malignancies Detection Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Hematologic Malignancies Detection Sales Value by Region
5.1.1 Global Hematologic Malignancies Detection Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Hematologic Malignancies Detection Sales Value by Region (2019-2024)
5.1.3 Global Hematologic Malignancies Detection Sales Value by Region (2025-2030)
5.1.4 Global Hematologic Malignancies Detection Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Hematologic Malignancies Detection Sales Value, 2019-2030
5.2.2 North America Hematologic Malignancies Detection Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Hematologic Malignancies Detection Sales Value, 2019-2030
5.3.2 Europe Hematologic Malignancies Detection Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Hematologic Malignancies Detection Sales Value, 2019-2030
5.4.2 Asia Pacific Hematologic Malignancies Detection Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Hematologic Malignancies Detection Sales Value, 2019-2030
5.5.2 South America Hematologic Malignancies Detection Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Hematologic Malignancies Detection Sales Value, 2019-2030
5.6.2 Middle East & Africa Hematologic Malignancies Detection Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Hematologic Malignancies Detection Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Hematologic Malignancies Detection Sales Value
6.3 United States
6.3.1 United States Hematologic Malignancies Detection Sales Value, 2019-2030
6.3.2 United States Hematologic Malignancies Detection Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Hematologic Malignancies Detection Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Hematologic Malignancies Detection Sales Value, 2019-2030
6.4.2 Europe Hematologic Malignancies Detection Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Hematologic Malignancies Detection Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Hematologic Malignancies Detection Sales Value, 2019-2030
6.5.2 China Hematologic Malignancies Detection Sales Value by Type (%), 2023 VS 2030
6.5.3 China Hematologic Malignancies Detection Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Hematologic Malignancies Detection Sales Value, 2019-2030
6.6.2 Japan Hematologic Malignancies Detection Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Hematologic Malignancies Detection Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Hematologic Malignancies Detection Sales Value, 2019-2030
6.7.2 South Korea Hematologic Malignancies Detection Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Hematologic Malignancies Detection Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Hematologic Malignancies Detection Sales Value, 2019-2030
6.8.2 Southeast Asia Hematologic Malignancies Detection Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Hematologic Malignancies Detection Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Hematologic Malignancies Detection Sales Value, 2019-2030
6.9.2 India Hematologic Malignancies Detection Sales Value by Type (%), 2023 VS 2030
6.9.3 India Hematologic Malignancies Detection Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 ArcherDx
7.1.1 ArcherDx Profile
7.1.2 ArcherDx Main Business
7.1.3 ArcherDx Hematologic Malignancies Detection Products, Services and Solutions
7.1.4 ArcherDx Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.1.5 ArcherDx Recent Developments
7.2 Bio-Rad Laboratories
7.2.1 Bio-Rad Laboratories Profile
7.2.2 Bio-Rad Laboratories Main Business
7.2.3 Bio-Rad Laboratories Hematologic Malignancies Detection Products, Services and Solutions
7.2.4 Bio-Rad Laboratories Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.2.5 Bio-Rad Laboratories Recent Developments
7.3 sysmex
7.3.1 sysmex Profile
7.3.2 sysmex Main Business
7.3.3 sysmex Hematologic Malignancies Detection Products, Services and Solutions
7.3.4 sysmex Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.3.5 Invitae Recent Developments
7.4 Invitae
7.4.1 Invitae Profile
7.4.2 Invitae Main Business
7.4.3 Invitae Hematologic Malignancies Detection Products, Services and Solutions
7.4.4 Invitae Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.4.5 Invitae Recent Developments
7.5 NeoGenomics Laboratories
7.5.1 NeoGenomics Laboratories Profile
7.5.2 NeoGenomics Laboratories Main Business
7.5.3 NeoGenomics Laboratories Hematologic Malignancies Detection Products, Services and Solutions
7.5.4 NeoGenomics Laboratories Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.5.5 NeoGenomics Laboratories Recent Developments
7.6 Abbott Laboratories
7.6.1 Abbott Laboratories Profile
7.6.2 Abbott Laboratories Main Business
7.6.3 Abbott Laboratories Hematologic Malignancies Detection Products, Services and Solutions
7.6.4 Abbott Laboratories Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.6.5 Abbott Laboratories Recent Developments
7.7 Cancer Genetics
7.7.1 Cancer Genetics Profile
7.7.2 Cancer Genetics Main Business
7.7.3 Cancer Genetics Hematologic Malignancies Detection Products, Services and Solutions
7.7.4 Cancer Genetics Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.7.5 Cancer Genetics Recent Developments
7.8 Adaptive Biotechnologies Corporation
7.8.1 Adaptive Biotechnologies Corporation Profile
7.8.2 Adaptive Biotechnologies Corporation Main Business
7.8.3 Adaptive Biotechnologies Corporation Hematologic Malignancies Detection Products, Services and Solutions
7.8.4 Adaptive Biotechnologies Corporation Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.8.5 Adaptive Biotechnologies Corporation Recent Developments
7.9 Asuragen
7.9.1 Asuragen Profile
7.9.2 Asuragen Main Business
7.9.3 Asuragen Hematologic Malignancies Detection Products, Services and Solutions
7.9.4 Asuragen Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.9.5 Asuragen Recent Developments
7.10 Invivoscribe
7.10.1 Invivoscribe Profile
7.10.2 Invivoscribe Main Business
7.10.3 Invivoscribe Hematologic Malignancies Detection Products, Services and Solutions
7.10.4 Invivoscribe Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.10.5 Invivoscribe Recent Developments
7.11 Nanjing Shihejiyin Technology
7.11.1 Nanjing Shihejiyin Technology Profile
7.11.2 Nanjing Shihejiyin Technology Main Business
7.11.3 Nanjing Shihejiyin Technology Hematologic Malignancies Detection Products, Services and Solutions
7.11.4 Nanjing Shihejiyin Technology Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.11.5 Nanjing Shihejiyin Technology Recent Developments
7.12 Annaroad Gene Technology
7.12.1 Annaroad Gene Technology Profile
7.12.2 Annaroad Gene Technology Main Business
7.12.3 Annaroad Gene Technology Hematologic Malignancies Detection Products, Services and Solutions
7.12.4 Annaroad Gene Technology Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.12.5 Annaroad Gene Technology Recent Developments
7.13 BGI Genomics
7.13.1 BGI Genomics Profile
7.13.2 BGI Genomics Main Business
7.13.3 BGI Genomics Hematologic Malignancies Detection Products, Services and Solutions
7.13.4 BGI Genomics Hematologic Malignancies Detection Revenue (US$ Million) & (2019-2024)
7.13.5 BGI Genomics Recent Developments
8 Industry Chain Analysis
8.1 Hematologic Malignancies Detection Industrial Chain
8.2 Hematologic Malignancies Detection Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Hematologic Malignancies Detection Sales Model
8.5.2 Sales Channel
8.5.3 Hematologic Malignancies Detection Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

ArcherDx
Bio-Rad Laboratories
sysmex
Invitae
NeoGenomics Laboratories
Abbott Laboratories
Cancer Genetics
Adaptive Biotechnologies Corporation
Asuragen
Invivoscribe
Nanjing Shihejiyin Technology
Annaroad Gene Technology
BGI Genomics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂